- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prostate cancer
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 757KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 207KB)
Enzalutamide – March 2022
Enzalutamide: Capsule 40 mg; Xtandi®
Last updated
1 July 2022